about
Anticholinergic medication use and dementia: latest evidence and clinical implicationsCumulative use of strong anticholinergics and incident dementia: a prospective cohort studyIsoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezilHuman models as tools in the development of psychotropic drugsHigher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21 Norwegian nursing homes.Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID StudyCholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients.Cumulative anticholinergic exposure is associated with poor memory and executive function in older men.Anticholinergic drug burden in older people's brain - how well is it measured?Pharmacological models in Alzheimer's disease researchThe predictive value of an adjusted COPD assessment test score on the risk of respiratory-related hospitalizations in severe COPD patients.Anticholinergics: theoretical and clinical overview.Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjectsHippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia.Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study.Age-related decline in central cholinergic function demonstrated with scopolamine.The interaction between medical burden and anticholinergic cognitive burden on neuropsychological function in a geriatric primary care sample.The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.Differential cognitive effects of carbamazepine and gabapentin.Effects of (R)-alpha-methylhistamine and scopolamine on spatial learning in the rat assessed using a water maze.
P2860
Q28068339-DBD788A0-37BB-4C92-A1B4-B90EB79D27E8Q28255929-EBC75C56-8136-44DB-A51E-CAD771AC8652Q28478062-5F485DFF-411C-4202-85F6-A7E60AEB3B21Q30473426-151B500C-4402-45B4-80EB-2DD10765402BQ30559371-15852CE7-67E6-4696-A1B6-08AB7457AB1BQ34104256-16528B38-6B57-4481-8851-4EE51410E3A9Q35826703-0F859122-F9AF-4EF5-B923-E206C4E94EB9Q37163279-CB447B2E-9D77-49EB-AFF7-E1DB9DBCD5E4Q37396867-589E7070-F32D-425A-9899-013C9248878DQ37634389-C69DA28A-4779-4D74-9E5F-ED379F17848AQ38151217-402C3EF7-BCCB-4C42-A20F-BB1545FD0A0DQ38578433-D0222858-B4EB-44D0-8275-F85DF08B1EF6Q38753103-AB0FE5EC-FA9E-4D01-89BB-D414BE310104Q38769800-9A6D6E8D-AC83-4BF9-ABE5-C8EBC7BA2877Q38786004-EE62392D-F2E7-48FB-9ABB-BBE13BE9F4B8Q41634921-ED590815-A9CD-4C19-B06F-95505FDE7F7FQ48150837-EB790516-BE36-46F7-854E-E7978A9A48ADQ48565482-F7C3D6D9-8383-4964-ABB1-5420A9C2C89BQ49124075-28D3BE92-3777-4B7F-9320-366830A5CCEBQ50760709-CAAC21DA-8746-4877-866B-3A54E2F4E78FQ51973289-EB7091B4-C821-4896-BD7F-443BFF494FDFQ52032064-43D92CC6-7A74-400F-9F22-00A98664E5ABQ52217105-82D16FEE-8CC8-45A5-A8CD-0129659AEDF9
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Central anticholinergic hypersensitivity in aging.
@en
type
label
Central anticholinergic hypersensitivity in aging.
@en
prefLabel
Central anticholinergic hypersensitivity in aging.
@en
P2093
P2860
P1476
Central anticholinergic hypersensitivity in aging.
@en
P2093
P2860
P356
10.1177/002383099200500203
P577
1992-04-01T00:00:00Z